Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06414408

Randomized Directly Observed Therapy Study to Interpret Clinical Trials of Doxy-PEP

Rates of bacterial sexually transmitted infections (STIs) are rising globally, demanding innovative interventions beyond the scope of current efforts to prevent STIs. The United States Doxycycline Post-exposure Prophylaxis (DoxyPEP) Study has demonstrated the efficacy of doxycycline post-exposure prophylaxis (PEP) among men who have sex with men and transgender women; but puzzlingly, doxycycline PEP was found ineffective in cisgender women in the Kenyan doxycycline Post-Exposure Prophylaxis (dPEP) study, with preliminary data suggesting the low medication adherence may explain the null result. By study end, the investigators will have developed adherence measurement methods for doxycycline in hair, blood, and urine, and will use these techniques to help interpret the Kenyan dPEP study, and to examine the relative performance of these methods within the United States DoxyPEP trial, establishing adherence metrics for current and future rollout studies of doxycycline post-exposure prophylaxis

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

University of California, San Francisco/San Francisco General Hospital

San Francisco, California, 94110, United States

Location status: Recruiting

Location contact

Matthew A Spinelli, MD, MAS

CONTACT

[email protected]

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • not currently at risk of a sexually transmitted infection and willing to use other methods, such as condoms, for STI prevention;
  • if diagnosed with an STI in the past two years and/or a partner was diagnosed with an STI in the past year, is willing to use condoms for STI prevention;
  • willing to provide hair, blood, and urine samples;
  • not currently enrolled in other STI prevention studies;
  • able to speak English
  • transgender women participants should be currently using estrogen gender affirming hormone therapy with blood estrogen levels demonstrating consistent use
  • transgender men participants should be currently using testosterone gender affirming hormone therapy with blood testosterone levels demonstrating consistent use
  • able to provide a hair sample of ~50-100 strands of hair that are non-gray, not bleached, and at least 1cm in length
  • willing to NOT shave hair or have a very short haircut or apply bleach for the duration of the study
  • has suitable venous access for consecutive blood draws

Exclusion criteria

  • any health condition that may interfere with participation or the ability to provide informed consent, including any debilitating or life-threatening conditions;
  • pregnancy or plans to become pregnant;
  • liver cirrhosis or fulminant liver disease;
  • known hypersensitivity reaction to doxycycline.
  • detectable doxycycline in hair at enrollment.
  • unable to provide a hair sample of ~50-100 strands of hair that are non-gray, not bleached, and at least 1cm in length
  • does not have suitable venous access for consecutive blood draws

Treatment and study plan

Doxycycline Pill

Drug

200mg Dose

Primary outcomes

  1. Hair Doxycycline Concentration

    Time frame: 4 weeks

    Doxycycline concentrations will be measured using liquid chromatography tandem mass spectrometry within hair samples for each of the four dosing patterns within an intensive washout pharmacokinetic phase following initial dosing.

  2. Plasma Doxycycline Concentration

    Time frame: 4 weeks

    Doxycycline concentrations will be measured using liquid chromatography tandem mass spectrometry within plasma samples for each of the four dosing patterns within an intensive washout pharmacokinetic phase following initial dosing.

  3. Urine Doxycycline Concentration

    Time frame: 4 weeks

    Doxycycline concentrations will be measured using liquid chromatography tandem mass spectrometry within urine samples for each of the four dosing patterns within an intensive washout pharmacokinetic phase following initial dosing.

Study contacts

Contact information is provided by the study sponsor or research team.

Shivani Mahuvakar

CONTACT

[email protected]

415-878-6384

Sponsors and collaborators

Lead sponsor

University of California, San Francisco

Other

Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

Registry information

Acronym: DOT-Doxy-PEP

Important dates

Study start
2024
Primary completion
2026
Study completion
2028
First posted
May 16, 2024
Registry last updated
Apr 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.